NASDAQ · TNDM
Healthcare · Medical - Devices
$16.50
Up+$0.00 (+0.00%)
Updated Oct 3, 2026, 12:05 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TNDM
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
TNDM closed at $16.50 after 19 trading sessions, down 17.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $16.42 | $16.58 | $16.04 | $16.50 | 2.4M |
| Sep 30, 2026 | $16.63 | $16.68 | $16.00 | $16.31 | 2.2M |
| Sep 29, 2026 | $16.24 | $16.645 | $15.87 | $16.57 | 1.89M |
| Sep 28, 2026 | $15.60 | $16.535 | $15.52 | $16.42 | 2.85M |
| Sep 25, 2026 | $15.20 | $16.18 | $14.83 | $15.72 | 2.84M |
| Sep 24, 2026 | $16.43 | $16.602 | $15.20 | $15.22 | 2.65M |
| Sep 23, 2026 | $17.44 | $17.67 | $15.865 | $16.38 | 2.81M |
| Sep 22, 2026 | $17.88 | $18.03 | $16.97 | $17.50 | 2.69M |
| Sep 21, 2026 | $17.01 | $17.83 | $16.60 | $17.62 | 2.1M |
| Sep 18, 2026 | $17.13 | $17.15 | $16.77 | $16.87 | 2.28M |
| Sep 17, 2026 | $17.72 | $17.72 | $16.93 | $17.23 | 2.22M |
| Sep 16, 2026 | $16.305 | $18.00 | $16.12 | $17.53 | 3.87M |
| Sep 15, 2026 | $16.66 | $17.005 | $16.25 | $16.28 | 2.38M |
| Sep 14, 2026 | $17.18 | $17.62 | $16.60 | $16.81 | 2.2M |
| Sep 11, 2026 | $18.48 | $18.67 | $17.065 | $17.11 | 1.79M |
| Sep 10, 2026 | $18.77 | $19.05 | $18.095 | $18.31 | 1.59M |
| Sep 9, 2026 | $19.67 | $19.73 | $19.035 | $19.11 | 1.57M |
| Sep 8, 2026 | $19.51 | $20.62 | $19.34 | $19.88 | 1.64M |
| Sep 4, 2026 | $20.04 | $20.36 | $19.49 | $19.90 | 1.36M |
The latest Smart Investors Daily articles mentioning TNDM.
Company
Market Activity
Research & News
TNDM research
Company profile and research snapshot.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | Citigroup | Neutral | — |
| Sep 24, 2026 | Truist Securities | Buy | — |
| Aug 21, 2026 | William Blair | Outperform | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 28, 2026
MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
Yahoo · Sep 23, 2026
A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.
Yahoo · Sep 20, 2026
Tandem Diabetes Care (TNDM) is back in focus after recent share price swings, with the stock closing at US$16.87. Investors are weighing mixed return figures and fresh financial data on revenue and profit. The share price of US$16.87 comes after a sharp 24.42% decline in the 1 month share price return. However, the 3 month share price return is up 17.64%, and the 1 year total shareholder return of 34.21% indicates momentum that has been building over a longer period, despite weaker 3 and 5...
SeekingAlpha · Sep 11, 2026
Tandem Diabetes Care has strong insulin-pump tech, but ongoing losses and cash burn threaten viability. Click here to read this TNDM stock update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TNDM.
